Truflation has partnered with QuantAMM and Chainlink to create the Truflation Blockchain-Traded Fund. BTF will use Chainlink’s CRE to deliver real-time inflation data from the TRUF Network into QuantAMM’s smart contracts. Truf Network, supported by Truflation, has rolled out a new product: the “Bitcoin BTF,” a blockchain-traded fund developed alongside QuantAMM, the DeFi protocol known [...]]]>Truflation has partnered with QuantAMM and Chainlink to create the Truflation Blockchain-Traded Fund. BTF will use Chainlink’s CRE to deliver real-time inflation data from the TRUF Network into QuantAMM’s smart contracts. Truf Network, supported by Truflation, has rolled out a new product: the “Bitcoin BTF,” a blockchain-traded fund developed alongside QuantAMM, the DeFi protocol known [...]]]>

Chainlink Drives On-Chain Innovation With Truflation-Powered Bitcoin Trading Strategy

  • Truflation has partnered with QuantAMM and Chainlink to create the Truflation Blockchain-Traded Fund.
  • BTF will use Chainlink’s CRE to deliver real-time inflation data from the TRUF Network into QuantAMM’s smart contracts.

Truf Network, supported by Truflation, has rolled out a new product: the “Bitcoin BTF,” a blockchain-traded fund developed alongside QuantAMM, the DeFi protocol known for its automated on-chain portfolio management infrastructure.

The strategy is powered by Truflation’s real-world economic data and made possible through the Chainlink Runtime Environment (CRE). Truflation itself is a crypto-native data provider that tracks inflation and economic trends.

In its announcement on X, Truflation explained that,

As real-time inflation data starts flowing directly into DeFi, traders and builders can finally link big-picture economic shifts to how crypto assets behave. Think of it like seeing how rising consumer prices might boost Bitcoin’s appeal as a hedge and then being able to act on that insight automatically.

Truflation has taken this a step further by creating a trend-regime detection model that can spot the moment a disinflationary period is ending and do it in real time. They first tested this model in a leveraged trading strategy, which ended up outperforming simple DCA approaches.

And while traditional ETFs only rebalance at set intervals and rely on centralized managers, the BTF adjusts continuously. Smart contracts update their allocations automatically, following clear, rules-based signals.

According to QuantAMM’s backtesting, the Truflation Bitcoin BTF beat both a pure BTC HODL strategy and a more conservative 50/50 BTC–USDC portfolio.

The Chainlink Runtime Environment handles everything behind the scenes. From pulling in real-time data to verifying it and delivering it on-chain, which removes a huge amount of operational overhead. Every action it triggers is backed by cryptographic verification, so smart contracts only run when the inputs can be trusted.

Chainlink Runtime Environment is also built with the reliability and security that institutional strategies expect. As we previously explained, it offers strong uptime and resilience without requiring developers to maintain their own nodes or custom integrations. And because CRE can coordinate logic across multiple chains and environments, it gives projects the flexibility to grow beyond Ethereum whenever they’re ready.

]]>
Market Opportunity
RealLink Logo
RealLink Price(REAL)
$0.0728
$0.0728$0.0728
+0.08%
USD
RealLink (REAL) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26